582 terminated. 582 Phase 2, 88 Phase 1, 56 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 582 | Terminated 582 |
| Phase 1 | 88 | Terminated 88 |
| Phase 3 | 56 | Terminated 56 |
Follow Brain Diseases: new trials by email Literature Review of Brain Diseases trials Research Report on Brain Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of GS3-007a for Oral Suspension in the Diagnosis of Adult Growth Hormone Deficiency (AGHD) GS3-007a dry suspension, Insulin - Adult Growth Hormone Deficiency (AGHD) | Phase 2 | Terminated | Changchun GeneScience Pharmaceutical Co., Ltd. | 120 | 2025-12-19 | 2026-05-22 |
| ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly ALXN2420, Placebo - Acromegaly | Phase 2 | Terminated | Alexion Pharmaceuticals, Inc. | 8 | 2025-10-28 | 2026-08-07 |
| A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients With Overt Hepatic Encephalopathy VS-01 on top of SOC (Active Treatment Group), SOC - Hepatic Encephalopathy, Acute on Chronic Liver Failure (ACLF) | Phase 2 | Terminated | Genfit | 3 | 2025-08-25 | 2026-01-12 |
| An Open-label Extension Safety Study of MELAS Patients Who Completed TIS6463-203 (PRIZM) zagociguat 15mg - Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome) | Phase 2 | Terminated | Tisento Therapeutics | 37 | 2025-08-18 | 2026-11-06 |
| A Study of K-645 in the Treatment of Multiple Migraine Attacks K-645 100 mg, K-645 10 mg, Placebo - Migraine | Phase 2 | Terminated | TriGemX Bio, Inc. | 134 | 2025-08-13 | 2026-11-05 |
| Extension Study of Participants From SPG302-ALZ-101 SPG302 - Alzheimer's Disease | Phase 2 | Terminated | Spinogenix | 12 | 2025-03-25 | 2025-12-18 |
| Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatic Colorectal Cancer Tiragolumab, Atezolizumab, Bevacizumab - Microsatellite Stable (MSS) Colorectal Cancer (CRC), Metastatic Colorectal Cancer (CRC) | Phase 2 | Terminated | University of Colorado, Denver | 13 | 2025-03-25 | 2026-11-20 |
| A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson's Disease VENT-02, Placebo - Parkinson Disease | Phase 1 / Phase 2 | Terminated | Ventus Therapeutics U.S., Inc. | 29 | 2025-03-05 | 2025-10-29 |
| A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008) MK-1167, Placebo - Alzheimer Disease, Dementia | Phase 2 | Terminated | Merck Sharp & Dohme LLC | 369 | 2024-12-16 | 2026-07-01 |
| Study of ASN51 in Adults With Early Alzheimer's Disease ASN51, Placebo - Alzheimer Disease | Phase 2 | Terminated | Asceneuron S.A. | 123 | 2024-10-16 | 2025-06-29 |
| Ultrasonic Neuromodulation for Treatment of Cognitive Impairment Diadem prototype - Alzheimer Disease, Dementia | Phase 1 / Phase 2 | Terminated | University of Utah | 1 | 2024-08-18 | 2025-05-25 |
| A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures BHV-7000, Placebo - Generalized Epilepsy | Phase 2 / Phase 3 | Terminated | Biohaven Therapeutics Ltd. | 27 | 2024-06-20 | 2026-03-24 |
| Safety and Pharmacodynamics of SHR-1707 in Alzheimer's Disease Patients SHR-1707, SHR-1707 placebo - Alzheimer's Disease | Phase 2 | Terminated | Shanghai Hengrui Pharmaceutical Co., Ltd. | 46 | 2024-02-05 | 2026-05-13 |
| Intranasal Ketorolac Trial Ketorolac, Prochlorperazine, Diphenhydramine - Headache, Migraine | Phase 2 | Terminated | Washington University School of Medicine | 41 | 2024-01-01 | 2026-01-16 |
| Insulin-sensitizing NE3107 in Improving Sleep and Fatigue in Subjects With Traumatic Brain Injury NE3107 - Traumatic Brain Injury | Phase 2 | Terminated | Neurological Associates of West Los Angeles | 4 | 2023-12-21 | 2025-07-25 |
| A Phase 2, Randomized, Prospective Double-Blind, Single-Center, Placebo-controlled Study to Evaluate Safety, Tolerability, Target Engagement, and Efficacy of PrimeC in Patients With Mild to Moderate Alzheimer's Disease. PrimeC, Placebo - Alzheimer Disease | Phase 2 | Terminated | NeuroSense Therapeutics Ltd. | 8 | 2023-11-19 | 2026-04-09 |
| Maimonides Minocycline in Stroke Study Minocycline - Stroke, Acute, Ischemic Stroke | Phase 2 / Phase 3 | Terminated | Maimonides Medical Center | 2 | 2023-11-01 | 2025-12-17 |
| High-Dose Ambroxol in GBA1-Related Parkinson Ambroxol Hydrochloride - Parkinson Disease, GBA Gene Mutation | Phase 1 / Phase 2 | Terminated | Agyany Pharma LTD | 46 | 2023-10-24 | 2026-11-09 |
| Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease GSK4527226, Placebo - Alzheimer's Disease | Phase 2 | Terminated | GlaxoSmithKline | 367 | 2023-10-20 | 2026-09-17 |
| Study to Evaluate the Efficacy and Safety of Staccato Apomorphine (AZ-009) in Patients With Parkinson's Disease Experiencing OFF Episodes Apomorphine Cartridge - Parkinson Disease | Phase 2 | Terminated | Alexza Pharmaceuticals, Inc. | 8 | 2023-09-27 | 2025-10-21 |
Showing 20 of 582. Sign in to see all of them.
Brain Neoplasms (117) · Alzheimer Disease (84) · Stroke (60) · Parkinson Disease (50) · Glioblastoma (42) · Ischemic Stroke (33) · Glioma (28) · Epilepsy (24) · Dementia (23) · Astrocytoma (20) · Brain Injuries, Traumatic (19) · Gliosarcoma (19) · Melanoma (18) · Migraine Disorders (17) · Neoplasm Metastasis (16)
Nervous System Diseases (575) · Central Nervous System Diseases (574) · Neurodegenerative Diseases (162) · Pathological Conditions, Signs and Symptoms (149) · Neoplasms by Site (138) · Nervous System Neoplasms (136) · Neoplasms (135) · Cardiovascular Diseases (127) · Vascular Diseases (125) · Central Nervous System Neoplasms (123) · Cerebrovascular Disorders (119) · Mental Disorders (117) · Neurocognitive Disorders (107) · Dementia (86)
Temozolomide (21) · Bevacizumab (11) · Radiotherapy (7) · Saline Solution (7) · Donepezil (6) · Cannabidiol (5) · Capecitabine (5) · Sodium Chloride (5) · pasireotide (5) · Carboplatin (4) · Erlotinib Hydrochloride (4) · Magnetic Resonance Spectroscopy (4) · Nivolumab (4) · Radiation (4) · Radiosurgery (4)
Pfizer (16) · National Cancer Institute (NCI) (12) · Novartis Pharmaceuticals (11) · Merck Sharp & Dohme LLC (10) · GlaxoSmithKline (7) · Biogen (6) · Eisai Inc. (6) · Johns Hopkins University (6) · Neurocrine Biosciences (6) · AbbVie (5) · Ipsen (5) · M.D. Anderson Cancer Center (5) · Wave Life Sciences USA, Inc. (5) · Columbia University (4) · Duke University (4)
United States (401) · Canada (84) · United Kingdom (77) · Germany (75) · France (72) · Spain (61) · Italy (50) · Australia (49) · Belgium (33) · Netherlands (33) · Poland (28) · Japan (22) · Israel (20) · South Korea (18) · Sweden (17)
PMID 29480210, PMID 32250312, PMID 40603145, PMID 12411660, PMID 12749708, PMID 15014939, PMID 15791633, PMID 16648043, PMID 16673051, PMID 17143244, PMID 17188664, PMID 17470830, PMID 17881719, PMID 18234750, PMID 18413464, PMID 18418368, PMID 19654233, PMID 20042969, PMID 20185783, PMID 20571524, PMID 20634684, PMID 21419704, PMID 21468088, PMID 21565557, PMID 21586746, PMID 21700934, PMID 21784661, PMID 21865400, PMID 21873264, PMID 22198309, PMID 22340437, PMID 23615499, PMID 23622977, PMID 23686372, PMID 23733308, PMID 23943316, PMID 24045608, PMID 24152824, PMID 24207098, PMID 24363954, PMID 24412048, PMID 24588854, PMID 24691436, PMID 25090617, PMID 25107879, PMID 25669746, PMID 25671797, PMID 25689146, PMID 25803346, PMID 25973909
2015 (11), 2017 (9), 2009 (8), 2016 (8), 2008 (5), 2014 (5), 2018 (5), 2019 (5), 2005 (2), 2023 (2), P50NS044148 (2), U01CA137443 (2), 1UF1AG046150-01 (1), 2004 (1), 2025 (1)